Marek Drozdz
Director of Research RenBio
Marek Drozdz, PhD, is a translational research leader with expertise in molecular biology, drug discovery, and clinical development. Currently serving as Director of Research at RenBio, he drives innovative therapeutic strategies for metabolic and chronic diseases. With a strong foundation in both academia and industry, Marek previously held postdoctoral research positions at Weill Cornell Medicine and the University of Oxford, where he earned his PhD in Cellular and Molecular Biology.
His career spans preclinical research, clinical trial operations (including a role at Roche), and leadership in scientific innovation as President of the Innovation Forum. Marek’s multidisciplinary background, bridging bench science, translational medicine, and biotech development positions him as a dynamic voice in obesity drug development.
Seminars
- Investigating a novel DNA-based platform for sustained in vivo GLP-1 production following a single administration
- Examining DNA electroporation for delivery of brain-targeted incretin mimetics for precise hunger modulation
- Assessing strategies for half-life extension of incretin to reduce dosing frequencies for improved patient adherence
- Expanding the therapeutic arsenal to target neuronal and metabolic pathways for more effective obesity treatments
- Demonstrating superior fat-loss preservation and GI tolerability in next-gen incretin therapies with brain-specific mechanisms to enable personalised obesity treatment
- Innovating delivery systems from DNA-encoded therapies to oral formulations for sustained peptide delivery
